Part Four Of Five: Pfizer's Q1 2024 Lobby Spending: Pretty High, In An Election Year...

We will head out shortly, on mountain bikes by the lake. . . to find our treasured taco trucks -- and dine al fresco on some perfect soft pollo tacos with cilantro and lime and avocados. It is the day for it -- as above would indicate.

But first, we here post part four of our five parter, on lobby spending -- this time, Pfizer's. Both Merck and Lilly have wildly outperformed much larger Pfizer over the last six or so quarters, on both earnings and the per share trading prices on NYSE. It remains to be seen whether PFE might get its mojo back -- but it seems to be banking on a change in administrations, as part of its strategy. Me? I think that's a. . . bad bet. In any event, here's the Pfizer Q1 deets:

. . .Pandemic Preparedness/PAHPA; Drug Pricing/Inflation Reduction Act: HR7174; Medicare Price Setting. . . .

PBM Transparency and Reform: S1375/HH830 - Help Ensure Lower Patient (HELP) Copays Act; S1542/HR6283 - Delinking Revenue from Unfair Gouging (DRUG) Act; S2973 - Modernizing and Ensuring PBM Accountability Act; S3430 - Better Mental Health Care, Lower Cost Drugs, and Extenders Act; HR5378 - Lower Costs More Transparency Act. . . .

Inflation Reduction Act / Medicare Price Setting; 340B Reform; Cell and Gene Therapy Access Model; HR1458 - Access to Prescription Digital Therapeutics Act of 2023. . . .

VICP Reform and Excise Tax. . . .

International Supply Chain; Global Access to Medicines; Pandemic Preparedness. . . .

Only Amgen left to go now -- likely Monday or Tuesday. Onward grinning, ear to ear.

नमस्ते